HRD testing has life-changing consequences for every woman with ovarian cancer, and MyChoice® is here to guide treatment decisions for each one.
MyChoice® examines ovarian cancer tumors by combining BRCA1 & 2 mutation analysis with a Genomic Instability Score, for comprehensive and accurate HRD results.1-4 MyChoice® identifies the right patients for PARP inhibitor treatment in time, and is the most validated HRD test in ovarian cancer.1,5-8
MyChoice® accurately identifies more HRD+ patients than tests that measure BRCA1 & 2 status or loss of heterozygosity alone,1-4 ensuring clinicians have the most accurate information to make informed treatment decisions.
Local testing with MyChoice® allows easy ordering and fast results, supporting clinicians to identify eligible patients for PARPi treatment in time.
MyChoice® is a trusted partner, as the only HRD test with FDA approval,9 CE certification, recommendation in major international treatment guidelines10-12 and the most prospective phase III study data.1,5-8
Learn more about MyChoice®
I’m a clinician
I’m a patient